TY - JOUR
T1 - From Premalignant Biology to Precision Interception
T2 - Connecting the Dots with a Curated Collection of Invited Articles
AU - Maresso, Karen Colbert
AU - Maitra, Anirban
AU - Hawk, Ernest T.
AU - Vilar, Eduardo
N1 - Funding Information:
A. Maitra reports other support from Cosmos Wisdom Biotechnology, Freenome, and Tezcat Biotechnology outside the submitted work; in addition, A. Maitra has a patent for Thrive Earlier Detection, an Exact Sciences Company issued to Johns Hopkins University. A. Maitra is supported by the MD Anderson Pancreatic Cancer Moon Shot Program, P50CA221707, and U54CA274371. A. Maitra is also supported by the Sheikh Khalifa Bin Zayed Al-Nahyan Foundation. E.T. Hawk reports grants from 5P30CA016672-47 NCI Cancer Center Support Grant and other support from T. Boone Pickens Distinguished Chair for Early Cancer Prevention - endowed faculty position outside the submitted work. E. Vilar reports other support from Janssen Research and Development outside the submitted work; and consulting or advisory role with Janssen Research and Development, Recursion Pharma, Guardant Health, and Tornado/Cambrian. No disclosures were reported by the other author.
Funding Information:
This work was supported by MD Anderson’s Strategic Research Initiative Development (STRIDE) program; and CA016672 (U.S. NIH/NCI) to The University of Texas MD Anderson Cancer Center, Core Support Grant.
Publisher Copyright:
© 2023 American Association for Cancer Research.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Nearly all cancers have identifiable histologically defined precursors known as precancers. These precancers offer a window of opportunity to intercept the neoplastic process to prevent its development into invasive cancer. However, lack of knowledge regarding the evolution of precancers and the microenvironmental pressures shaping them precludes efforts to intercept them. Technological developments over the past decade have facilitated the study of precancers at a previously unattainable resolution. Calls for a national PreCancer Atlas effort incorporating these technologies were heeded in 2018, with the launch of the Human Tumor Atlas Network (HTAN) as part of the Beau Biden National Cancer Moonshot. Since then, five funded HTAN groups have focused their efforts on profiling precancers from breast, colon, skin, and lung. In this time, what progress has been made? What is next for HTAN and the field of premalignant biology? And are there lessons that individual investigators and the larger prevention field can learn from this initial effort to accelerate the development of novel early detection methods, risk prediction biomarkers, and interception agents? A special collection of invited reviews by experts in cancer evolution, systems biology, immunology, cancer genetics, preventive agent development, among other areas, attempts to answer these questions.
AB - Nearly all cancers have identifiable histologically defined precursors known as precancers. These precancers offer a window of opportunity to intercept the neoplastic process to prevent its development into invasive cancer. However, lack of knowledge regarding the evolution of precancers and the microenvironmental pressures shaping them precludes efforts to intercept them. Technological developments over the past decade have facilitated the study of precancers at a previously unattainable resolution. Calls for a national PreCancer Atlas effort incorporating these technologies were heeded in 2018, with the launch of the Human Tumor Atlas Network (HTAN) as part of the Beau Biden National Cancer Moonshot. Since then, five funded HTAN groups have focused their efforts on profiling precancers from breast, colon, skin, and lung. In this time, what progress has been made? What is next for HTAN and the field of premalignant biology? And are there lessons that individual investigators and the larger prevention field can learn from this initial effort to accelerate the development of novel early detection methods, risk prediction biomarkers, and interception agents? A special collection of invited reviews by experts in cancer evolution, systems biology, immunology, cancer genetics, preventive agent development, among other areas, attempts to answer these questions.
UR - http://www.scopus.com/inward/record.url?scp=85164245140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164245140&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-23-0081
DO - 10.1158/1940-6207.CAPR-23-0081
M3 - Article
C2 - 37403656
AN - SCOPUS:85164245140
SN - 1940-6207
VL - 16
SP - 365
EP - 368
JO - Cancer Prevention Research
JF - Cancer Prevention Research
IS - 7
ER -